Studying Daily Patterns of Urinary Copper Levels in Wilson Disease Patients Treated with D-Penicillamine, Trientine, or Zinc Salts

What this Trial Is About

Wilsons Disease is a genetic disorder that causes copper to build up mainly in the liver and brain. Researchers are studying how urinary copper levels vary throughout the day in patients with Wilsons Disease who are treated with medicines that remove copper or reduce its absorption. The goal is to find the best time of day to measure copper in urine to better estimate the bodys copper load and adjust treatment. The study involves three groups of patients aged 6 to 70 years, all confirmed to have Wilsons Disease. Each group is treated with one of three treatments D-Penicillamine, Trientine, or Zinc salts. Patients will provide three urine samples collected over 8-hour periods and one blood sample to assess liver function and copper levels. The study is observational and aims to compare spot urine copper levels at different times with the standard 24-hour urine copper measurement. Participants will undergo urine and blood tests to measure copper excretion and liver function. Researchers will analyze the correlation between different urine collection periods and the standard 24-hour urine copper levels. This monitoring will help determine the optimal urine collection time for evaluating copper elimination. The study will last until February 2027, and participants must be able to perform 24-hour urine collection as part of the study assessments.

Circadian Variation of Urinary Copper Excretion in Wilson Disease Patients